JA, H., MP, M., S, D., MM, W., M, G., R, J., . . . GS, C. (2021). Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety. Journal of medical virology, 93(4), 2270. https://doi.org/10.1002/jmv.26674
Chicago Style (17th ed.) CitationJA, Hill, et al. "Tocilizumab in Hospitalized Patients with COVID-19: Clinical Outcomes, Inflammatory Marker Kinetics, and Safety." Journal of Medical Virology 93, no. 4 (2021): 2270. https://doi.org/10.1002/jmv.26674.
MLA (9th ed.) CitationJA, Hill, et al. "Tocilizumab in Hospitalized Patients with COVID-19: Clinical Outcomes, Inflammatory Marker Kinetics, and Safety." Journal of Medical Virology, vol. 93, no. 4, 2021, p. 2270, https://doi.org/10.1002/jmv.26674.
Warning: These citations may not always be 100% accurate.
